In the wake of the tragedy associated with a nationwide fungal meningitis outbreak tied to contaminated injectable methylprednisolone acetate and triamcinolone acetonide manufactured by the New England Compounding Center (NECC), the ASDSA strives to provide the most current information about how our members may be affected. Please check this page often for updates, and click on the links below for further information.
**ASDSA Position Statement on Compounding Pharmacies**
Watch the 60 Minutes segment on the NECC (first aired March 10, 2013)
Information about the voluntary Ameridose recall
FDA response to Lidocaine Hydrocholoride Injection shortage
New bill designed to provide stronger oversight of compounding pharmacies
ASDSA press release urging stronger oversight of compounding pharmacies